Debate: Transplant vs. CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
English
Recorded Courses
hosted by National Comprehensive Cancer Network (NCCN)
hosted by National Comprehensive Cancer Network (NCCN)
attend it anywhere online
category
Healthcare Management, Nursing, Medicine
Nurse Practitioners, Oncology, Hematology
price
Free
Debate: Transplant vs. CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma is organized by National Comprehensive Cancer Network (NCCN) and will be held from Dec 15, 2022 - Dec 15, 2023.,,Description:,The advent of CAR T-cell therapy represents a major paradigm shift for management of patients with relapsed or refractory diffuse large B-cell lymphomas (DLBCL). The choice of treatment for relapsed or refractory DLBCL should be based on the response to second-line therapy, timing of relapse, eligibility to undergo transplant, access to CAR T-cell therapy and patient/physician preference. Educating clinicians about the recent clinical advances and the benefits/risks associated with the use of transplant and CAR T-cell therapy can help them to make informed clinical decisions for individual patients.,,Learning Objectives:,Following this program, participants should be able to:,• Summarize the evidence from clinical trials supporting the use of high-dose therapy followed by autologous hematopoietic cell transplant for patients with relapsed/refractory diffuse large B-cell lymphomas (DLBCL).,• Review the safety and efficacy of currently approved CAR T-cell therapies and other targeted therapies for relapsed or refractory DLBCL.,• Develop an individualized treatment plan for patients with relapsed/refractory DLBCL.,,Additional details will be posted as soon as information is available.